A5038170474- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Breast Lesions and Carcinomas
- Breast Implant and Reconstruction
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Reconstructive Surgery and Microvascular Techniques
- Economic and Financial Impacts of Cancer
- RNA Interference and Gene Delivery
- DNA Repair Mechanisms
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Advances in Oncology and Radiotherapy
- Pancreatic function and diabetes
- Cancer Genomics and Diagnostics
- Nutrition, Genetics, and Disease
- Signaling Pathways in Disease
- Clinical practice guidelines implementation
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- CRISPR and Genetic Engineering
- Cancer Risks and Factors
Queen's University Belfast
2016-2025
Orbsen Therapeutics (Ireland)
2024
Belfast City Hospital
2011-2023
Belfast Health and Social Care Trust
2011-2023
University of Ulster
2011-2023
Albury Wodonga Health
2023
Charing Cross Hospital
2023
Imperial College London
2023
Laboratoire des Sciences de l'Ingénieur, de l'Informatique et de l'Imagerie
2022
NIHR Birmingham Biomedical Research Centre
2021
PURPOSE As part of the ENTHUSE (Endothelin A Use) program, efficacy and safety zibotentan (ZD4054), an oral specific endothelin receptor antagonist, has been investigated in combination with docetaxel patients metastatic castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS In this randomized, double-blind, placebo-controlled, phase III study, received intravenous 75 mg/m(2) on day 1 21-day cycles plus 10 mg or placebo once daily. The primary end point was overall survival (OS)....
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of palbociclib plus letrozole as neoadjuvant PATIENTS AND METHODS Postmenopausal women ER-positive primary BC and tumors greater than or equal 2.0 cm were randomly assigned 3:2:2:2 (2.5 mg/d) for 14 weeks (A); 2 weeks, then (B); (C); weeks. Palbociclib 125 mg/d was administered orally...
Cancer is a leading cause of disease burden globally, with more than 19·3 million cases and 10 deaths recorded in 2020. Research crucial to understanding the determinants cancer effects interventions, improving outcomes. We aimed analyse global patterns public philanthropic investment research.In this content analysis, we searched UberResearch Dimensions database UK data for human research funding awards from funders between Jan 1, 2016, Dec 31, Included award types were project programme...
Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women, is characterized by high secretion levels of LH and T. Currently, there no treatment licensed specifically for PCOS.The objective this study was to investigate whether a targeted therapy would decrease pulse frequency women with PCOS, subsequently reducing serum T concentrations thereby presenting novel therapeutic approach management PCOS.This double-blind, double-dummy, placebo-controlled, phase 2 trial.University...
Germline mutations in BRCA1 predispose carriers to a high incidence of breast and ovarian cancers. functions maintain genomic stability through critical roles DNA repair, cell-cycle arrest, transcriptional control. A major question has been why loss or mutation leads tumors mainly estrogen-regulated tissues, given that essential all cell types. Here, we report estrogen metabolites can cause double-strand breaks (DSB) receptor-α-negative cells is required repair these DSBs prevent...
Abstract Background The B-MaP-C study aimed to determine alterations breast cancer (BC) management during the peak transmission period of UK COVID-19 pandemic and potential impact these treatment decisions. Methods This was a national cohort patients with early BC undergoing multidisciplinary team (MDT)-guided recommendations pandemic, designated ‘standard’ or ‘COVID-altered’, in preoperative, operative post-operative setting. Findings Of 3776 (from 64 units) study, 2246 (59%) had...
RNA-sequencing (RNA-seq) is a relatively new technology that lacks standardisation. RNA-seq can be used for Differential Gene Expression (DGE) analysis, however, no consensus exists as to which methodology ensures robust and reproducible results. Indeed, it broadly acknowledged DGE methods provide disparate Despite obstacles, assays are in advanced development clinical use but further optimisation will needed. Herein, five models (DESeq2, voom + limma, edgeR, EBSeq, NOISeq) gene-level...
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation 2 expansion cohorts: Module 1A paired biopsy cohort solid tumor patients, 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, 2A fulvestrant combination HR+/HER2− post-CDK4/6-inhibitor. Core primary...
Genitourinary syndrome of menopause can be treated with vaginal estrogen therapy. However, there are concerns about the safety therapy in patients breast cancer.
To report the final analysis of a Phase II trial, which investigated safety and efficacy specific endothelin A receptor antagonist zibotentan (AstraZeneca, Macclesfield, UK) in patients with metastatic castration-resistant prostate cancer (CRPC).Patients CRPC bone metastases who were pain free or mildly symptomatic for randomized to receive once-daily oral tablets 10 mg, 15 mg placebo. The primary endpoint was time progression secondary endpoints included overall survival, change number...
Abstract BACKGROUND: Endothelin‐1 and the endothelin A (ET ) receptor have been implicated in prostate cancer progression bone. This study aimed to determine whether specific ET antagonist, zibotentan, prolonged overall survival (OS) patients with castration‐resistant bone metastases who were pain‐free or mildly symptomatic for pain. METHODS: Patients randomized 1:1 zibotentan 10 mg/day placebo, plus standard treatment. The primary endpoint was OS. Secondary endpoints included times pain...
FK506-binding protein like (FKBPL) and its peptide derivative, AD-01, have already shown tumor growth inhibition CD44-dependent antiangiogenic activity. Here, we explore the ability of AD-01 to target CD44-positive breast cancer stem cells (BCSC).Mammosphere assays flow cytometry were used analyze effect FKBPL overexpression/knockdown treatment ± other anticancer agents on BCSCs using cell lines (MCF-7/MDA-231/ZR-75), primary patient samples, xenografts. Delays in initiation evaluated vivo....
Optimising breast cancer treatment remains a challenge. Resistance to therapy is major problem in both ER- and ER+ cancer. Tumour recurrence after chemotherapy and/or targeted leads more aggressive tumours with enhanced metastatic ability. Self-renewing stem cells (CSCs) have been implicated resistance, the development of disease. In this study, we utilised vitro, vivo ex models using MCF-7 MDA-MB-231 cells, as well solid patient samples, interrogate effects FKBPL its peptide therapeutics on...
Aims To conduct a definitive multicentre comparison of digital pathology (DP) with light microscopy (LM) for reporting histopathology slides including breast and bowel cancer screening samples. Methods A total 2024 cases (608 breast, 607 GI, 609 skin, 200 renal) were studied, 207 250 Cases examined by four pathologists (16 study across the speciality groups), using both LM DP, order randomly assigned 6 weeks between viewings. Reports compared clinical management concordance (CMC), meaning...
Introduction Neoadjuvant systemic anticancer therapy (neoSACT) is increasingly used in the treatment of early breast cancer. Response to prognostic and allows locoregional adjuvant treatments be tailored minimise morbidity optimise oncological outcomes quality life. Accurate information about following neoSACT vital allow translation downstaging benefits into practice facilitate meaningful interpretation outcomes, particularly recurrence. Reporting studies, however, currently poor. The...
Abstract Purpose To use robust consensus methods with individuals lived breast cancer experience to agree the top 10 research priorities improve information and support for patients undergoing surgery in UK. Methods Research uncertainties related submitted by carers were analysed thematically generate summary questions inclusion an online Delphi survey. Individuals completed two rounds including feedback which they selected their from list provided. The most highly ranked survey discussed at...